TipRanks
Go Ultimate55% OFF

Gerresheimer (GXIN) Stock Price & Analysis

GXIN Stock Chart & Stats

MX$672.05MX$0.00(0.00%)
At close:
Mex$550Mex$600Mex$65019 Aug14 Sep22 Sep20 Oct
Day’s Range
MXN 672.05 - MXN 672.05
52-Week Range
MXN 347.84 - MXN 1,649.75
Previous Close
MXN 672.05
Volume
0
Average Volume (3M)
12
Market Cap
MXN 23.22B
Enterprise Value
MXN 3.53B
Total Cash (Recent Filing)
MXN 167.61M
Total Debt (Recent Filing)
MXN 2.21B
Price to Earnings (P/E)
―
Beta
0.29
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
0.13%

Bulls Say, Bears Say

Bulls Say

Steady Revenue Growth

Revenue growth across several years indicates expanding demand for Gerresheimer’s pharmaceutical packaging and delivery products. Continued top-line expansion provides a durable base for operating leverage and supports investment in specialized products, customer programs, and future capacity.

Positive Operating Cash Flow

Positive operating cash flow demonstrates that the core business continues to convert customer sales into cash despite recent profitability challenges. This underlying cash generation supports ongoing operations and provides some internal funding capacity for investment and debt servicing.

Recurring Healthcare Demand

Products used to store, protect, and administer medicines are tied to continuing pharmaceutical production rather than purely discretionary purchases. Long-term customer relationships and recurring volume demand can support business resilience and make specialized solutions harder to replace.

Bears Say

Swing To Net Loss

The shift from consistent operating profitability in 2020–2024 to substantial EBIT and net losses in 2025 is a material deterioration in earnings quality. If not reversed, weaker profitability could reduce reinvestment capacity and undermine returns from the company’s growing revenue base.

Higher Leverage

Rising debt alongside a shrinking equity base increases financial risk and reduces flexibility during an operating downturn. Greater leverage can constrain capital allocation, raise dependence on financing, and make it harder for Gerresheimer to absorb further earnings weakness.

Deeply Negative Free Cash Flow

Large negative free cash flow means positive operating cash generation is not covering investment, working-capital needs, or other cash uses. Persistent cash conversion weakness increases reliance on external financing, which is especially concerning while debt is rising and earnings are negative.

Gerresheimer News

GXIN FAQ

What was Gerresheimer’s price range in the past 12 months?
Gerresheimer lowest stock price was Mex$347.84 and its highest was Mex$1649.75 in the past 12 months.
What is Gerresheimer’s market cap?
Gerresheimer’s market cap is Mex$23.22B.
When is Gerresheimer’s upcoming earnings report date?
Gerresheimer’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 115 days.
How were Gerresheimer’s earnings last quarter?
Gerresheimer released its earnings results on Oct 30, 2026. The company reported Mex$5.727 earnings per share for the quarter.
Is Gerresheimer overvalued?
According to Wall Street analysts Gerresheimer’s price is currently Overvalued.
Does Gerresheimer pay dividends?
Gerresheimer does not currently pay dividends.
What is Gerresheimer’s EPS estimate?
Gerresheimer’s EPS estimate is 15.65.
How many shares outstanding does Gerresheimer have?
Gerresheimer has 34,540,000 shares outstanding.
What happened to Gerresheimer’s price movement after its last earnings report?
Gerresheimer reported an EPS of Mex$5.727 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gerresheimer?
Currently, no hedge funds are holding shares in MX:GXIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology